MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Award Announcements & Progress Reports: Federal Contracts, Grants & Cooperative Agreements
*2018: SDVOSB Awardees_CIO-SP3 Small Business Ramp On Open Season_Solicitation Number NIHJT2016015, Award
TechWerks, LLC (technologywerks) (SDVOSB)
San Antonio, Texas
2026: OPMED 2026_Operational Medicine (OpMed) SYMPOSIUM & TECHNOLOGY SHOWCASE March 17-18 2026, San Antonio, Texas
Organon & Co. (NYSE:OGN)*
Organization & Developments: Organon
Parents
Organon & Co. (NYSE:OGN)*
Children
*Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia
*Organon: Q3 Results Show Promising Acquisitions But Mixed Portfolio Sales
2022: Organon designed the Jada system to control and treat abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.
2022: Organon: Thoughts Ahead Of Q3 Earnings_seekingalpha.com
2023: High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued_seekingalpha.com
2024: FDA blesses atopic dermatitis label expansions for Organon's Vtama, Galderma's Nemluvio
2024: Organon & Co. 2023 Q4 - Results - Earnings Call Presentation
2024: Organon & Co.: Cheap With Caveats
2024: Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last
2024: Organon Stock Is Still Worth A Look
2024: Organon to buy Roivant's dermatology unit for up to $1.2 billion
2024: Organon: 7% Yield, 4x P/E, Big Upside Potential
2024: Organon: A Surprising Deal
2024: Organon's SWOT analysis: stock poised for growth amid challenges
2025: Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield
2025: Organon: Persistent Headwinds Make This A Hold
Jumps
Finance & Acquisitions: Organon
Key People: Organon